MELBOURNE, Australia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highlighted the potential of its lead proenzyme therapy, PRP, as a novel approach that could compete with existing approved therapies for solid tumors, particularly in areas of high unmet need such as pancreatic cancer. PRP is a proprietary intraven ...

Core Insights - Propanc Biopharma, Inc. has filed its fourth new provisional patent application in two months, focusing on innovative formulations of pancreatic proenzymes, which are critical for addressing challenges in stability and transport for biomedical applications [1][2] - The company aims to double its intellectual property portfolio from approximately 90 to over 200 patents, covering various aspects of its proenzyme technology, which targets and prevents metastasis from solid tumors [2][3] - Propanc's lead asset, PRP, is designed to selectively attack cancer stem cells and circulating tumor cells while sparing healthy tissue, offering a potential long-term therapy with reduced toxicity compared to conventional treatments [3][4] Company Developments - The recent patent applications are part of a strategy to secure leadership in a field with significant unmet medical needs, particularly for aggressive cancers with limited treatment options [2][3] - Preparations for a Phase 1b First-In-Human study of PRP in advanced cancer patients are advancing rapidly, with expectations for further updates on the clinical pathway and broader pipeline soon [3] Industry Context - Propanc is developing a novel approach to cancer treatment by targeting cancer stem cells through proenzyme activation, which addresses the underlying drivers of cancer proliferation and spread [4]

Core Insights - Propanc Biopharma has filed a provisional patent application for a fully synthetic recombinant version of PRP, aimed at treating and preventing metastatic cancer from solid tumors [1][3] - The global metastatic cancer market is projected to reach $111 billion by 2027, indicating significant market potential for Propanc's innovations [1] - The synthetic version of trypsinogen and chymotrypsinogen, named Rec-PRP, offers advantages such as longer shelf life and suitability for distribution in regions lacking refrigeration [2] Company Developments - The recent patent application is the third filed in two months, enhancing the company's intellectual property portfolio as it prepares for national phase applications worldwide [3] - The company is focused on developing a platform technology that targets cancer stem cells, aiming to provide a treatment option with fewer side effects compared to standard therapies [4] - Propanc is also expanding its research into other therapeutic areas with significant unmet medical needs, indicating a strategic approach to long-term growth [3]

Core Insights - Propanc Biopharma is focused on developing novel treatments for chronic diseases, particularly pancreatic cancer, which has a high unmet medical need due to low survival rates and ineffective traditional therapies [1][4] Group 1: Product Overview - Propanc's lead clinical candidate, PRP, is a proprietary mixture of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, formulated in a 1:6 ratio and administered intravenously [2] - PRP is designed to target cancer stem cells and modulate processes linked to metastasis and drug resistance, such as the epithelial to mesenchymal transition (EMT) [2] Group 2: Clinical Development - The FDA granted Orphan Drug Designation to PRP in 2017 for pancreatic cancer treatment, acknowledging the severe unmet need [3] - Propanc plans to initiate Phase I/II clinical trials in 2026, starting with dose-finding studies and progressing to proof-of-concept studies in pancreatic and other cancers [4] Group 3: Market Opportunity - The global pancreatic cancer therapeutics market is projected to grow from approximately USD 2.9 billion in 2024 to around USD 5.8 billion by 2030, representing a CAGR of about 12.3% [7] - The broader pancreatic cancer market, including therapies and diagnostics, is expected to expand from approximately USD 3.25 billion in 2025 to over USD 10.25 billion by 2034, with a CAGR of around 13.6% [7] - The pancreatic cancer segment targeted by PRP is forecasted to reach roughly USD 6.93 billion by 2030, with the total addressable market for PRP, including ovarian cancer, estimated between USD 14 billion to USD 18 billion over the next decade [12] Group 4: Mechanistic Findings - PRP has shown potential in preclinical studies by reducing angiogenesis and cell migration in pancreatic cancer models, as well as reversing EMT markers associated with invasiveness [6] - Laboratory data suggest that PRP enhances chemosensitivity, making resistant pancreatic tumor cells more responsive to standard chemotherapies [6] - In vivo studies indicated significant tumor growth inhibition, with over 85% growth reduction at certain PRP doses compared to controls [6] Group 5: Financial Position - Propanc Biopharma is a pre-revenue biotechnology company focused on early-stage clinical development, with significant annual net losses primarily due to non-cash stock-based compensation [13] - A recent IPO raised approximately USD 4 million in gross proceeds, positioning the company for clinical advancement of PRP and a follow-on candidate [13] - The company has entered into structural financing arrangements, including a potential USD 100 million private placement facility to support further development [13]

Core Insights - Propanc Biopharma, Inc. has published significant findings regarding the impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts, highlighting the potential of PRP as a disruptor of the tumor microenvironment (TME) [1][3] - The company plans to conduct a Phase 1b study in Q3 2026 to evaluate PRP's efficacy in advanced cancer patients, particularly those with solid tumors, including PDAC [4] Company Overview - Propanc Biopharma, Inc. is focused on developing novel treatments for chronic diseases, specifically targeting cancer recurrence and metastasis through proenzyme activation [5] - The lead product candidate, PRP, consists of two bovine-derived pancreatic proenzymes, trypsinogen and chymotrypsinogen, which have shown efficacy in cancer treatment [1][5] Industry Context - PDAC is one of the most aggressive and deadliest forms of cancer, with projections indicating it may become the second leading cause of cancer-related deaths by 2030 [2] - The disease is characterized by late-stage diagnosis, limited treatment options, and poor prognosis, underscoring the need for innovative therapeutic strategies [2]

Core Insights - Propanc Biopharma, Inc. is investigating "mesenchymal drift" to understand the reversal of chronic diseases, particularly focusing on its lead product candidate, PRP, and its influence on epithelial-to-mesenchymal transition (EMT) pathways [1][3] - The company has filed a patent application for a PRP-based treatment method targeting fibrotic diseases, which are significant contributors to age-related organ failure [1][3] Company Overview - Propanc Biopharma, Inc. is developing innovative treatments aimed at preventing cancer recurrence and metastasis by targeting cancer stem cells through proenzyme activation [4] - The lead product candidate, PRP, consists of pancreatic proenzymes trypsinogen and chymotrypsinogen, which are administered intravenously [3][4] Research and Development - A Phase 1b First-In-Human study for PRP in patients with advanced solid tumors is scheduled to begin in 2026, focusing on determining the maximum tolerated dose [3] - Following the initial study, multiple Phase 2 proof-of-concept trials will be conducted to explore various indications, with the potential to achieve "blockbuster status" [3] Scientific Collaboration - The research team includes experts from Propanc and the University of Jaén, emphasizing the importance of PRP in addressing chronic diseases like cancer and fibrosis [3] - The investigation into PRP's effects on EMT and mesenchymal drift is seen as a promising direction for developing new rejuvenation strategies in medicine [3]

Core Insights - Propanc Biopharma has submitted a request for a foreign filing license from Spain for two provisional patents aimed at treating resistant cancer and fibrosis, marking a significant step in its research and development efforts [1][5] - The first patent focuses on methods to treat cancers that have developed resistance to chemotherapy and radiotherapy, addressing the urgent need for new strategies to prevent recurrence and treatment failure [2] - The second patent pertains to compositions and methods for treating fibrosis, which is characterized by excessive scar tissue accumulation and can affect various organ systems, significantly impacting morbidity and mortality [3] Patent Details - The first provisional patent addresses treatment methods for chemotherapy-resistant cancers, highlighting the ongoing high global mortality rates and the necessity for innovative approaches [2] - The second provisional patent represents a novel addition to Propanc's intellectual property portfolio, utilizing the lead product candidate PRP for chronic diseases beyond cancer, particularly focusing on the epithelial-to-mesenchymal transition (EMT) as a therapeutic target [4] Future Plans - The CEO of Propanc, James Nathanielsz, emphasized that the submission of these patents is a pivotal moment for the company, with plans for a Phase 1b, First-In-Human study in 2026 to determine the therapeutic dose of PRP [5] - The company aims to explore the application of PRP across multiple disease conditions in subsequent Phase 2 proof-of-concept studies, positioning it as a novel therapeutic approach that encourages normal cell behavior without the cytotoxic effects of standard treatments [5] Company Overview - Propanc Biopharma is focused on developing innovative treatments to prevent cancer recurrence and metastasis by targeting cancer stem cells through proenzyme activation, with its lead product candidate PRP designed to address the underlying drivers of cancer proliferation [6]

Core Insights - Propanc Biopharma, Inc. is advancing its lead candidate PRP towards a Phase 1b clinical trial for advanced solid tumors, with significant progress in GMP manufacturing and patent drafting [2][3][4] - The company has successfully raised $4 million through a public offering and entered a private placement agreement for up to $100 million to accelerate clinical development [5][6] - Financial results for Q1 show a net loss of $4.84 million, with total current assets at $17 million and a reduction in total current liabilities by $2 million [9][15] Corporate and R&D Highlights - PRP is set to enter a Phase 1b clinical study involving 30-40 patients at the Peter Mac Cancer Center, with purification processes achieving over 95% purity [2] - Rec-PRP, a synthetic version of PRP, is undergoing biological validation and will enter preclinical development after potency evaluation [3] - The POP1 research program is being extended to further investigate PRP's effects on Gemcitabine-resistant pancreatic cancer [4] Financial Updates - The company completed a public offering of 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 million [5] - A private placement facility of up to $100 million has been established, with an initial investment of $1 million received [6] - As of September 30, 2025, total current assets were reported at $17 million, with a quarter-end cash balance of $600,000 [9][15] Management Commentary - The CEO highlighted meaningful progress in clinical, financial, and strategic initiatives, emphasizing the focus on initiating the Phase 1b trial and expanding the intellectual property portfolio [8]

Core Insights - Propanc Biopharma, Inc. has entered into a securities purchase agreement with Hexstone Capital LLC for a private placement of up to $100 million in convertible preferred stock to support its digital asset acquisition strategy and accelerate its R&D pipeline [1][2] - The initial investment of $1 million was received upon closing, based on the issuance of 100 shares of Series C Convertible Preferred Stock, each with a par value of $0.01 and an initial stated value of $10,000 [1] - The company plans to enter a First-In-Human study for its lead product candidate, PRP, in the second half of 2026 [1] Financial Details - Propanc will issue 9,900 Warrants to Hexstone, each allowing the purchase of one share of Preferred Stock at $10,000 per share, totaling up to $99 million in potential funding [2] - The Warrants are immediately exercisable and valid for 12 months, with the company able to call up to 500 Warrants per calendar month at $0.01 each, allowing for the exercise of up to $5 million in Preferred Stock per month [2] Company Overview - Propanc Biopharma, Inc. is focused on developing treatments to prevent recurrence and metastasis in cancer patients by targeting cancer stem cells through proenzyme activation [4] - The company's lead product candidate, PRP, aims to address the root cause of cancer proliferation and spread [4]

Core Insights - Propanc Biopharma, Inc. has entered into a securities purchase agreement with Hexstone Capital LLC for a private placement of up to $100 million in convertible preferred stock to support its digital asset acquisition strategy and accelerate its R&D pipeline [1][2] - The initial investment of $1 million has been received, based on the issuance of 100 shares of Series C Convertible Preferred Stock, each with a par value of $0.01 and an initial stated value of $10,000 [1] - The company plans to enter a First-In-Human study for its lead product candidate, PRP, in the second half of 2026 [1] Financial Details - Propanc will issue 9,900 Warrants to Hexstone, each allowing the purchase of one share of Preferred Stock at $10,000 per share, totaling up to $99 million in potential funding [2] - The Warrants are immediately exercisable and valid for 12 months, with the company able to call up to 500 Warrants per calendar month at $0.01 each, allowing for the exercise of up to $5 million in Preferred Stock per month [2] Company Overview - Propanc Biopharma, Inc. is focused on developing treatments to prevent recurrence and metastasis in cancer patients by targeting cancer stem cells through proenzyme activation [4] - The company's lead product candidate, PRP, aims to address the root cause of cancer proliferation and spread [4]